EX-4.2
from 8-K
5 pages
Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 11, 2020, Among (I) Wright Medical Group, Inc., a Delaware Corporation (The “Company”); (II) Wright Medical Group N.V., a Dutch Public Limited Company (Naamloze Vennootschap) (The “Guarantor”); (III) Wright Luxembourg S.A., a Luxembourg Société Anonyme (“Wright Luxembourg”) and a Wholly Owned Subsidiary of the Company; (IV) Wright Medical Ltd., a Bermuda Exempted Company (“Wright Bermuda”) and a Wholly Owned Subsidiary of Wright Luxembourg; and (V) the Bank of New York Mellon Trust Company, N.A., as Trustee (The “Trustee”)
12/34/56
EX-4.1
from 8-K
5 pages
Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 11, 2020, Among (I) Wright Medical Group N.V., a Dutch Public Limited Company (Naamloze Vennootschnovember 8, 2020ap) (The “Company”); (II) Wright Luxembourg S.A., a Luxembourg Société Anonyme (“Wright Luxembourg”) and a Wholly Owned Subsidiary of the Company; (III) Wright Medical Ltd., a Bermuda Exempted Company (“Wright Bermuda”) and a Wholly Owned Subsidiary of Wright Luxembourg; and (IV) the Bank of New York Mellon Trust Company, N.A., as Trustee (The “Trustee”)
12/34/56
EX-4.1
from 8-K
5 pages
Supplemental Indenture (This “Supplemental Indenture”), Dated as of November 24, 2015, Among (I) Wright Medical Group, Inc., a Delaware Corporation (The “Company”); (II) Wright Medical Group N.V., a Dutch Public Limited Company (Naamloze Vennootschap) (The “Guarantor”); and (III) the Bank of New York Mellon Trust Company, N.A., as Trustee (The “Trustee”)
12/34/56